A French cohort study comparing the safety and efficacy of Ticagrelor with Clopidogrel and Prasugrel in patient hospitalised for Acute Coronary Syndrome (ACS)
Latest Information Update: 19 Sep 2017
Price :
$35 *
At a glance
- Drugs Ticagrelor (Primary) ; Clopidogrel; Prasugrel
- Indications Acute coronary syndromes
- Focus Adverse reactions; Therapeutic Use
- Acronyms SNIIRAM
- 19 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management